Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.3, replacing v3.5.2. This reflects a site-wide version update and does not change the study details or user interactions.
    Difference
    0.1%
    Check dated 2026-04-30T15:26:45.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision note updated from v3.5.0 to v3.5.2 on the page.
    Difference
    0.1%
    Check dated 2026-04-16T11:00:22.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Added a site revision note: v3.5.0 and removed the previous revision note: v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-18T17:44:11.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.2 to v3.4.3. No study data or essential content appears to be affected.
    Difference
    0.1%
    Check dated 2026-03-11T14:48:02.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added; the previous 'Notice about government funding' and 'Revision: v3.4.1' items were removed.
    Difference
    0.4%
    Check dated 2026-02-11T01:33:19.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding was added, informing users that information may not be up to date and directing them to opm.gov for updates. The page revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-03T22:24:44.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.